Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03714737
Recruitment Status : Completed
First Posted : October 22, 2018
Last Update Posted : October 22, 2018
Sponsor:
Information provided by (Responsible Party):
Jiangsu Province Centers for Disease Control and Prevention

Brief Summary:
Invasive meningococcal disease and meningococcal meningitis caused by Neisseria meningitidis have their highest incidence in children, with a second peak in adolescents and young adults. The most important disease-causing serogroups are meningococcal serogroups A (MenA) and MenC in Asia, such as China. The specific vaccine use in each country depends on the predominant serogroups, cost, and availability. conjugate vaccines are preferred to polysaccharide vaccines due to their impact on decreasing nasopharyngeal carriage of N. meningitidis and their overall increased immunogenicity in children. This clinical trial is planning to evaluate the immunogenicity and safety of bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine in Chinese healthy children aged 3 months to 5 years.

Condition or disease Intervention/treatment Phase
Vaccine Biological: experimental vaccine Biological: Positive control vaccine 1 Biological: Positive control vaccine 2 Phase 3

Detailed Description:
Invasive meningococcal disease and meningococcal meningitis caused by Neisseria meningitidis have their highest incidence in children, with a second peak in adolescents and young adults. The most important disease-causing serogroups are meningococcal serogroups A (MenA), MenB, MenC, MenW and MenY. Their prevalence varies geographically, MenA and MenC being more prominent in Asia. Neisseria meningitidis is one of the leading causes of bacterial meningitis globally. The annual number of cases related to invasive meningococcal disease (IMD) is estimated to be at least 1.2 million with 135 000 deaths.1 To combat IMD, an increasing number of countries have included vaccines against N. meningitidis in their routine immunization programs. The specific vaccine use in each country depends on the predominant serogroups, cost, and availability. Polysaccharide vaccines were used in high risk people in Saudi Arabia and Syria and in routine immunization in China and Egypt. In general, conjugate vaccines are preferred to polysaccharide vaccines due to their impact on decreasing nasopharyngeal carriage of N. meningitidis and their overall increased immunogenicity in children. This clinical trial is planning to evaluate the immunogenicity and safety of bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine in Chinese healthy children aged 3 months to 5 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1950 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese Healthy Children Aged 3 Months to 5 Years.: A Randomized, Blinded, Positive Controlled Phase III Clinical Trial
Actual Study Start Date : May 12, 2016
Actual Primary Completion Date : September 11, 2017
Actual Study Completion Date : September 6, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tetanus

Arm Intervention/treatment
Experimental: Experimental 1
Experimental vaccine of 0.5ml in 300 children aged 2-5 years at day 0.
Biological: experimental vaccine
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Active Comparator: Positive control 1
Positive control vaccine 1 of 0.5ml in 300 children aged 2-5 years at day 0.
Biological: Positive control vaccine 1
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)

Experimental: Experimental 2
Experimental vaccine of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
Biological: experimental vaccine
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Experimental: Experimental 3
Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0.
Biological: experimental vaccine
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Active Comparator: Positive control 2
Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
Biological: Positive control vaccine 2
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)

Experimental: Experimental 4
Experimental vaccine of 0.5ml in 150 children aged 2-5 years at day 0 and 28, and boost at 18 months.
Biological: experimental vaccine
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Active Comparator: Positive Control 3
Positive control vaccine 2 of 0.5ml in 150 children aged 6-11 months at day 0 and 28.
Biological: Positive control vaccine 2
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)

Experimental: Experimental 5
Experimental vaccine of 0.5ml in 300 children aged 3-5 months at day 0, 28, 56, and boost at 18 months.
Biological: experimental vaccine
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Active Comparator: Positive Control 4
Positive control vaccine 1 of 0.5ml in 300 children aged 3-5 months day 0, 28, 56.
Biological: Positive control vaccine 1
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)




Primary Outcome Measures :
  1. seroconversion rates of antibodies after vaccination [ Time Frame: 28 days after vaccination ]
    seroconversion rates of antibodies against meningococcal serogroups A and C

  2. Proportion of subjects reporting solicited injection-site reactions, solicited systemic reactions [ Time Frame: Day 7 post-each dose ]
    Proportion of subjects reporting solicited injection-site reactions, solicited systemic reactions within 7 days post-each dose


Secondary Outcome Measures :
  1. Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 2-5 years. [ Time Frame: 28 days after vaccination ]
    Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C at day 28 post vaccination in children aged 2-5 years.

  2. Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 12-23 months. [ Time Frame: 28 days after vaccination ]
    Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 12-23 months with two vaccination schedules.

  3. Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 6-11 months. [ Time Frame: 28 days after vaccination ]
    Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 6-11 months.

  4. Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 3-5 months. [ Time Frame: 28 days after vaccination ]
    Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 3-5 months.

  5. Proportion of subjects reporting unsolicited adverse events [ Time Frame: 28 days after vaccination ]
    Proportion of subjects reporting unsolicited adverse events

  6. Proportion of subjects with Serious Adverse Events occurring throughout the trial [ Time Frame: 28 days after vaccination ]
    Proportion of subjects with Serious Adverse Events occurring throughout the trial



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Months to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 3-5 months old group
  • Healthy infants aged 3-5months old as established by medical history and clinical examination
  • Subjects who was never administered meningococcal vaccine.
  • The subjects' guardians are able to understand and sign the informed consent
  • Subjects who can and will comply with the requirements of the protocol
  • Subjects with temperature ≤37.0°C on axillary setting 6-23 months old group
  • Healthy infants aged 6-23 months old as established by medical history and clinical examination
  • Subjects who was never administered meningococcal conjugate vaccine, or administered meningococcal polysaccharide vaccine over 3 months.
  • The subjects' guardians are able to understand and sign the informed consent
  • Subjects who can and will comply with the requirements of the protocol
  • Subjects with temperature ≤37.0°C on axillary setting 2-5 years old group
  • Healthy infants aged 2-5 years as established by medical history and clinical examination
  • Subjects who was never administered meningococcal conjugate vaccine, or administered meningococcal polysaccharide vaccine over 12 months.
  • The subjects' guardians are able to understand and sign the informed consent
  • Subjects who can and will comply with the requirements of the protocol
  • Subjects with temperature ≤37.0°C on axillary setting

Exclusion Criteria:

  • Subjects who has a medical history of invasive meningococcal disease and meningococcal meningitis.
  • Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine
  • Severe malnutrition or dysgenopathy
  • Family history of seizures or progressive neurological disease
  • Family history of congenital or hereditary immunodeficiency
  • Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with injections or blood draws
  • Any acute infections in last 3 days
  • Any prior administration of immunodepressant or corticosteroids in last 14 days
  • Any prior administration of attenuated live vaccine in last 14 days
  • Any prior administration of subunit or inactivated vaccines in last 7 days
  • Had fever before vaccination, Subjects with temperature >37.0°C on axillary setting
  • Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Exclusion Criteria for the second and third dose:

If Subjects who have one condition as followed, prohibiting to continue the vaccination, and they will be continue observed in the opinion of the investigator. All participants with adverse events as followed, must be settled in follow-up to the end of events.

  • Any serious adverse events caused by vaccination.
  • Any confirmed or suspected autoimmune diseases or immune deficiency disorders, including human immunodeficiency virus (HIV) infection
  • Have acute or new chronic disease during vaccination
  • Other reactions that in the opinion of the investigator ( include: severely serious symptom of pain, swelling, Limitation of motion, continuous high fever, headache and other Systemic or local reactions )

Layout table for additonal information
Responsible Party: Jiangsu Province Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT03714737     History of Changes
Other Study ID Numbers: JSVCT028
First Posted: October 22, 2018    Key Record Dates
Last Update Posted: October 22, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tetanus
Clostridium Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs